TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02587819
Drug: Treatment with BSCT
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing.
Study: NCT01433562
Drug: DLBS1425
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Study: NCT01433562
Drug: Placebo DLBS1425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Study: NCT00464503
Drug: Rosuvastatin-Crestor
Normalized name: rosuvastatin Oral Tablet [Crestor]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00464503
Drug: Pravastatin-Pravasine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00623870
Drug: RO5045337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT04113668
Drug: diflunisal
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT01563263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: phosphate buffered saline (PBS) solution containing 0,9 % NaCl
Study: NCT04519463
Drug: Xylocaine Mucosal Product
Normalized name: Xylocaine Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine 10% Nasal Spray
Study: NCT04519463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9%
Study: NCT00575965
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets taken daily
Study: NCT03077919
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: preservative-free normal saline
Study: NCT02771717
Drug: Placebo - dummy inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - dummy inhaler to be taken 1 puff twice daily.
Study: NCT04102995
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration
Study: NCT02798978
Drug: GSK1795091
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
Study: NCT02798978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
Study: NCT03738618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Study: NCT00198627
Drug: Co-Trimoxazole; TMP-SMZ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01080677
Drug: caffeine/propranolol combination tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: caffeine/propranolol combination tablet administered orally once daily
Study: NCT01080677
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match caffeine/propranolol combination tablet administered orally once daily
Study: NCT01281540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo tablet 4 times a day for 8 weeks
Study: NCT00003346
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02089841
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
Study: NCT02673619
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
Study: NCT01429701
Drug: polymyxin B sulphate + prednisolone + benzocaine + clioquinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied 3 times / day at lesion
Study: NCT02799212
Drug: placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
Study: NCT01429701
Drug: betamethasone + gentamicin + tolnaftato + cleoquinol
Normalized name: betamethasone / gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied 3 times / day at lesion
Study: NCT06630481
Drug: neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
Study: NCT01369589
Drug: P-552
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
Study: NCT01369589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
Study: NCT00627367
Drug: Nonprotocolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV opioid the type and dose of which will be determined by the treating clinician
Study: NCT00680459
Drug: 70% ethanol
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [Anatizer S 70% Ethanol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
Study: NCT00680459
Drug: heparin flush solution
Normalized name: heparin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
Study: NCT05122312
Drug: Olinanoseal
Approvals — FDA: no, EMA: no, PMDA: no
Description: it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
Study: NCT01768364
Drug: Trimetoprim-Sulfa (Bactrim)
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04055909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05122312
Drug: Curodont D'senz
Approvals — FDA: no, EMA: no, PMDA: no
Description: This agent contains p 11-4 peptide in addition to fluoride
Study: NCT02018757
Drug: TACE containing As2O3
Approvals — FDA: no, EMA: no, PMDA: no
Description: transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Study: NCT02018757
Drug: TACE containing placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Study: NCT02301026
Drug: 5% Iron Isomaltoside 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to local routines and product labeling in doses at the doctors discretion
Study: NCT02092792
Drug: DLYE5953A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of DLYE5953A
Study: NCT02092792
Drug: DLYE5953A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of DLYE5953A at the recommended phase II dose (RP2D)
Study: NCT00536471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00533039
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
Study: NCT01903018
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02952001
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Study: NCT02597803
Drug: RGN-259
Approvals — FDA: no, EMA: no, PMDA: no
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Study: NCT02597803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study: NCT02801903
Drug: SB204 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically Once Daily (AM)
Study: NCT01500850
Drug: nph insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Study: NCT06068166
Drug: GDMT
Normalized name: Guideline-Directed Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
Study: NCT00140166
Drug: pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02604225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
Study: NCT00257686
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00992355
Drug: Tobramycin 0.3% - Dexamethasone 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00992355
Drug: Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00711646
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study: NCT00711646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT03549000
Drug: NIR178
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR178 Specified dose on specified days, Orally
Study: NCT00198848
Drug: Iron-folic acid supplement
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01302028
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00402363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00556153
Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
Study: NCT01800357
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of plabcebo once a day and for 14 days
Study: NCT01189695
Drug: optimized background regimens (OBRs)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background regimens such as NRTIs, etravirine or raltegravir
Study: NCT02454205
Drug: Kanamycin
Normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
Study: NCT01685710
Drug: GTN patch
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01685710
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will be a placebo patch to the active drug patch to blind the trial.
Study: NCT00690625
Drug: MyoRx Cream (6% Omega 3 Fatty Acid)
Normalized name: Myorx
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 teaspoon 3 times per day for 30 days.
Study: NCT00690625
Drug: Placebo cream, no Omega 3 fatty acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, no Omega 3 fatty acid
Study: NCT00538304
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye daily for 1 month
Study: NCT00757055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment given
Study: NCT00748371
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: one Avicel (cellulose) capsule by mouth twice daily
Study: NCT03539601
Drug: Hydrocortisone butyrate cream, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied BID
Study: NCT00465088
Drug: Niacin ER/Simvastatin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 2000 mg/40 mg at bedtime
Study: NCT01067144
Drug: Placebo (inactive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
Study: NCT05197517
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film Coated Tablets products containing 10 mg Rosuvastatin
Study: NCT00973687
Drug: Ora Sweet
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
Study: NCT03278028
Drug: A-101 Topical Solution
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 Topical Solution
Study: NCT00568321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03604796
Drug: Rectal Solution
Normalized name: Rectal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen at 15 mg/kg x 4/day for three days
Study: NCT03604796
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
Study: NCT00225719
Drug: rHDL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00506688
Drug: reduced glutathione sodium salt
Normalized name: ibuprofen, sodium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
Study: NCT00506688
Drug: 0.9% normal saline (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
Study: NCT01053988
Drug: FF/GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study: NCT01053988
Drug: GW642444 Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long Acting Beta Agonist(LABA)
Study: NCT01053988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03910712
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study: NCT03058783
Drug: IDP-124 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-124 Lotion, twice-daily application
Study: NCT00857142
Drug: oxymorphone hydrochloride
Normalized name: Oxymorphone Hydrochloride
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02225600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Placebo
Study: NCT00295867
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
Study: NCT02809573
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration
Study: NCT01693081
Drug: VR040/Aspirair® inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Powder inhaled apomorphine
Study: NCT01693081
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01137955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally three times a day for 10 days total
Study: NCT00129623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po monthly for 1 year
Study: NCT00129623
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 1 year
Study: NCT04632589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects ingest placebo tablet daily for 6 weeks
Study: NCT00983320
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01839877
Drug: HIA DEBIRI + systemic FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04204408
Drug: NNC0365-3769 (Mim8)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
Study: NCT04204408
Drug: Placebo (Mim8)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mim8 placebo administered subcutaneously (s.c., under the skin)
Study: NCT03334409
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00669487
Drug: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
Study: NCT00669487
Drug: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
Study: NCT00669487
Drug: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
Study: NCT00651638
Drug: Treatment with ARQ 197
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ARQ 197
Study: NCT01821378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Daily
Study: NCT03643965
Drug: Nefecon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefecon 16 mg for daily administration by mouth for 9 months.
Study: NCT03643965
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for daily administration by mouth for 9 months.
Study: NCT00303225
Drug: Vaccine: SIGA-246
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03593759
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, subcutaneous, or intramuscular methotrexate
Study: NCT00590863
Drug: SSRI + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
Study: NCT04214301
Drug: BLI800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI800 Bowel Preparation
Study: NCT03374540
Drug: Vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually adjusted dose
Study: NCT04209465
Drug: BDTX-189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
Study: NCT01683695
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
Study: NCT00828763
Drug: [14c}-GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-Integrase inhibitor labelled with a carbon 14 marker
Study: NCT00300313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 capsules
Study: NCT00665743
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500 mg
Study: NCT02091245
Drug: KPT-330
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01443702
Drug: Lapis Judaicus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g capsule per day.
Study: NCT01443702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g capsule per day.